OCREVUS, a treatment for multiple sclerosis (MS), showed strong sales growth of 9% in 2025, reaching about $7.6 billion globally. Its broad efficacy in treating both relapsing and progressive MS, along with the recent approval of a convenient subcutaneous injection, has expanded patient access and sustained prescription momentum. Despite competition from biosimilars, OCREVUS remains a key growth driver for Roche, supported by robust clinical data and ongoing research. Market forecasts predict continued growth through 2034 across major regions including the US, Europe, and Japan.
SAPHNELO (Anifrolumab), a monoclonal antibody for moderate-to-severe systemic lupus erythematosus (SLE), demonstrates robust clinical efficacy by targeting type I interferon receptors. Approved in over 70 countries, it generated $483 million in sales...
California Governor Gavin Newsom proposed a new tax extending state sales tax to digital prewritten software purchases, aiming to level the playing field between online and physical store sales. The tax, set to take effect January 1, 2027 pending leg...
New York Governor Kathy Hochul proposes a two-phase tax increase on luxury second homes in NYC to address the city's budget deficit. Initially, homes with at least $1 million assessed value will face a 4-6.5% surcharge, potentially translating to pro...
During a state visit to China, President Donald Trump pushed for broader access for U.S. credit card companies like Visa to enter China's financial market. Trump highlighted Visa's exclusion and expressed hope that restrictions might be lifted. This ...
Dysport, a botulinum toxin product by Ipsen, is projected to see strong sales growth through 2034, fueled by rising demand for minimally invasive aesthetic and therapeutic procedures. The expanding global neuromodulator market, competitive pricing ag...
